Houston e-commerce startup makes C-suite appointment and acquisition

growth mode

Here's the latest news from Cart.com. Photo via cart.com

In the past week, Houston-based Cart.com has made some big moves on its tech startup journey — including another strategic acquisition and new hire.

The end-to-end e-commerce-as-a-service provider, which recently raised a $98 million series B round of funding, announced Tony Puccetti as the company's new chief delivery officer following the acquisition of 180Commerce, a leading online sales partner.

Puccetti, who joins Cart.com from digital consultancy Blue Acorn, will manage all client deliverables for the company. Puccetti also previously served as general manager and senior vice president over e-commerce, strategym sales, and more at Onestop Internet.

"I've spent my career championing fast-growing brands in the retail space, so I recognized instantly that Cart.com's ability to deliver seamless end-to-end e-commerce support and services was a true gamechanger," Puccetti says in a news release. "I'm thrilled to be joining the team, and I'm looking forward to helping deliver the services and technologies that brands need to grow their business and realize their full potential in today's omnichannel world.

Cart.com hired Tony Puccetti as the company's new chief delivery officer. Photo via LinkedIn

Omair Tariq, Cart.com CEO, says Puccetti has the talent and experience the company's clients need.

"Cart.com has built a reputation for making big, bold promises — then delivering on them, and exceeding our customers' expectations as they scale their e-commerce brands," continues Tariq in the release. "We're delighted to be welcoming Tony to the Cart.com family, and we're looking forward to working with him to transform the tech-enabled commerce space for merchants of all sizes."

The news of Puccetti's appointment follows news of California-based 180Commerce's acquisition by Cart.com. The company was founded in 2016 following DSW's acquisition of Shoe Metro, the largest Amazon footwear reseller. According to the news release, leaders from Shoe Metro formed 180Commerce "to bring their expertise directly to brands through a tech-enabled agency service model." The company provides its clients with data-driven and tech-enabled retail strategies, tools, and resources.

"The 180Commerce value proposition has always focused on helping consumer brands grow long-term revenue and profitability by optimizing and streamlining their marketplace strategies. By joining with Cart.com, we're bringing that vision to a far wider audience while continuing to expand our offering to the brands we serve with the powerhouse of offerings Cart.com provides," says Jason Stuempfig, founder of 180Commerce. "We share Cart.com's vision for a no-hassle, fully integrated e-commerce ecosystem, and I'm delighted to be starting this new chapter in the 180Commerce story."

The acquisition means a merging of clients, services, and staff between the two companies. 180Commerce's full team will be onboarded to Cart.com under Stuempfig's leadership.

"We're thrilled to welcome the 180Commerce team into the Cart.com family as we continue to expand our offering of commerce everywhere," Tariq says in the release. "Jason turned 180Commerce into a success story by being relentlessly focused on delivering results for brands, while creating a powerful company culture in which everyone is valued. That's exactly the combination we look for at Cart.com — especially when it's paired with a commitment to using data and technology to streamline and optimize e-commerce and marketplace functions for fast-growing brands in every corner of the world."

This acquisition is the latest in a series for Cart.com. Previously, the company has acquired AmeriCommerce, Spacecraft Brands, DuMont Project, and Sauceda Industries.

"Acquisitions are central to Cart.com's growth strategy, and with the addition of 180Commerce we're underscoring our commitment to expanding into new areas and building out best-in-class capabilities across the full spectrum of e-commerce sales channels such as marketplaces," says Saheb Sabharwal, chief strategy officer at Cart.com, who leads all M&A activity, in the release. "We're looking forward to working with Jason and the 180Commerce team to drive new value for Cart.com's thousands of loyal users. We have a great process in place to integrate new companies into the Cart.com ecosystem, and we're actively seeking additional M&A opportunities as we augment our solutions for brands."

Remington Tonar, chief commercial officer and co-founder at Cart.com, also recently told InnovationMap of the company's plans on a recent episode of the Houston Innovators Podcast. Heading into the holidays, where potential new clients will be focusing on delivering on orders and sales, Tonar says Cart.com is expecting a busy 2022 in terms of growth. In a lot of ways, the COVID-19 pandemic played a major role in the development of e-commerce and, by extension, Cart.com.

"The pandemic has played a role in overall accelerating the growth of e-commerce as a category and an industry. That growth was going to happen anyways, but it made it more ubiquitous faster," Tonar says. "It's just commerce now. This is just how people purchase and consume things."

Stream the full podcast below.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup recognized for inclusivity on journey to commercialize next-gen therapeutics

future of medicine

A new Houston biotech company won a special award at the 16th Annual SXSW Pitch Award Ceremony earlier this month.

Phiogen, one of 45 companies that competed in nine categories, was the winner for best inclusivity, much to the surprise of the company’s CEO, Amanda Burkhardt.

Burkhardt tells InnovationMap that while she wanted to represent the heavily female patient population that Phiogen seeks to treat, really she just hires the most skilled scientists.

“The best talent was the folks that we have and it ends up being we have three green card holders on our team. As far as ethnicities, we have on our team we have Indian, African-American, Korean, Chinese Pakistani, Moroccan and Hispanic people and that just kind of just makes up the people who helped us on a day-to-day basis,” she explains.

Phiogen was selected out of 670 companies to be in the health and nutrition category at SXSW.

“We did really well, but there was another company that also did really well. And so we were not selected for the pitch competition, which we were a little bummed about because I killed the pitch,” Burkhardt recalls.

But Phiogen is worthy of note, pitch competition or not. The new company spun off from research at Dr. Anthony Maresso’s TAILOR Labs, a personalized phage therapy center at Baylor College of Medicine, last June.

“Our whole goal is to create the next generation of anti-infectives,” says Burkhardt.

That means that the company is making alternatives to antibiotics, but as Burkhardt says, “We’re hoping to be better than antibiotics.”

How does it work? Bacteriophages are viruses that infect bacteria.

“You can imagine them as the predators in the bacteria world, but they don't infect humans. They don't affect animals. They only infect bacteria,” Burkhardt explains.

Phiogen utilizes carefully honed bacteriophages to attack bacteria that include the baddies behind urinary tract infection (UTI), bacteremia (bacteria in the blood), and skin wounds.

The team’s primary focus is on treatment-resistant UTI. One example was a male patient who received Phiogen’s treatment thanks to an emergency-use authorization from the FDA. The gentleman had been suffering from an infection for 20 years. He was treated with Phiogen’s bacteriophage therapy for two weeks and completely cleared his infection with no recurrence.

Amanda Burkhardt is the CEO of Phiogen. Photo via LinkedIn

But Phiogen has its sights set well beyond the first maladies it’s treated. An oft-quoted 2016 report projected that by 2050, 10 million people a year will be dying from drug-resistant infections.

“A lot of scientists call it the silent pandemic because it's happening now, we're living in it, but there's just not as much being said about it because it normally happens to people who are already in the hospital for something else, or it's a comorbidity, but that's not always the case, especially when we're talking about urinary tract infections,” says Burkhardt.

Bacteriophages are important because they can be quickly trained to fight against resistant strains, whereas it takes years and millions of dollars to develop new antibiotics. There are 13 clinical trials that are currently taking place for bacteriophage therapy. Burkhardt estimates that the treatment method will likely gain FDA approval in the next five years.

“The FDA actually has been super flexible on progressing forward. Because they are naturally occurring, there's not really a safety risk with these products,” she says.

And Burkhardt, whose background is in life-science commercialization, says there’s no better place to build Phiogen than in Houston.

“You have Boston, you have the Bay [Area], and you have the Gulf Coast,” she says. “And Houston is cheaper, the people are friendlier, and it’s not a bad place to be in the winter.”

She also mentions the impressive shadow that Helix Park will cast over the ecosystem. Phiogen will move later this year to the new campus — one of the labs selected to join Baylor College of Medicine.

And as for that prize, chances are, it won’t be Phiogen’s last.

Houston student selected for prestigious health care research program

bright future

A Houston-area undergraduate student has been tapped for a prestigious national program that pairs early-career investigators with health research professionals.

Mielad Ziaee was selected for the National Institutes of Health’s 2023-2024 All of Us Research Scholar Program, which connects young innovators with experts "working to advance the field of precision medicine," according to a statement from UH. Ziaee – a 20-year-old majoring in psychology and minoring in biology, medicine and society who plans to graduate in 2025 — plans to research how genomics, or the studying of a person's DNA, can be used to impact health.

“I’ll be one of the ones that define what this field of personalized, precision medicine will look like in the future,” Ziaee said in a statement. “It’s exciting and it’s a big responsibility that will involve engaging diverse populations and stakeholders from different systems – from researchers to health care providers to policymakers.”

Ziaee aims to become a physician who can use an understanding of social health conditions to guide his clinical practice. At a young age, he was inspired to go into the field by his family's own experience.

According to UH, Ziaee is the oldest child of Iranian American immigrants. He saw firsthand the challenges of how language and cultural barriers can impact patients' access to and level of care.

“I think a lot of people define health as purely biological, but a lot of other factors influence our well-being, such as mental health, financial health, and even access to good food, medical care and the internet,” he said in a statement. “I am interested in seeing the relationship among all these things and how they impact our health. So far, a lot of health policies and systems have not really looked beyond biology.”

"I want everyone to have an equal chance to access health care and take charge of their well-being. We need to have the systems in place that let people do that,” he added.

Ziaee is already on his way to helping Houston-based and national health systems and organizations make headway in this area.

He was named as a student regent on the UH System Board of Regents last year, sits on the board of the Houston chapter of the American Red Cross, and is an Albert Schweitzer Fellow.

Last year he was a Centers for Disease Control and Prevention John R. Lewis scholar, for which he presented his research project about predicting food insecurity in pediatric clinical settings and recommendations to improve the assessment based off his summer research with the Johns Hopkins University School of Medicine and the Kennedy Krieger Institute.

Prior to this, he completed a 10-week guided research experience using data visualization and predictive modeling techniques to assess food insecurity in the Third Ward.

“I just took every opportunity that came to me,” Ziaee said. “All my experiences connect with my central desire to increase health access and improve health care. I am very intentional about connecting the dots to my passion.”

Earlier this year, three UH student researchers were named among 16 other early-stage research projects at U.S. colleges and universities to receive a total of $17.4 million from the DOE's Office of Fossil Energy and Carbon Management (FECM). The projects were each awarded between about $750,000 to up to $1.5 million.

Houston tech entrepreneur expands energy data co. in Europe, continues to scale

houston innovators podcast episode 229

The technology that Amperon provides its customers — a comprehensive, AI-backed data analytics platform — is majorly key to the energy industry and the transition of the sector. But CEO Sean Kelly says he doesn't run his business like an energy company.

Kelly explains on the Houston Innovators Podcast that he chooses to run Amperon as a tech company when it comes to hiring and scaling.

"There are a lot of energy companies that do tech — they'll hire a large IT department, they'll outsource a bunch of things, and they'll try to undergo a product themselves because they think it should be IP," he says on the show. "A tech company means that at your core, you're trying to build the best and brightest technology."

To Kelly, Amperon should be hiring in the same field as Google and other big tech companies that sit at the top of the market. And Kelly has done a lot of hiring recently. Recently closing the company's $20 million series B round last fall led by Energize Capital, Amperon has tripled its team in the past 14 months.

With his growing team, Kelly also speaks to the importance of partnerships as the company scales. Earlier this month, Amperon announced that it is replatforming its AI-powered energy analytics technology onto Microsoft Azure. The partnership with the tech giant allows Amperon's energy sector clients to use Microsoft's analytics stack with Amperon data.

And there are more collaborations where that comes from.

"For Amperon, 2024 is the year of partnerships," Kelly says on the podcast. "I think you'll see partnership announcements here in the next couple of quarters."

Along with more partners, Amperon is entering an era of expansion, specifically in Europe, which Kelly says has taken place at a fast pace.

"Amperon will be live in a month in 25 countries," he says.

While Amperon's technology isn't energy transition specific, Kelly shares how it's been surprising how many clean tech and climate tech lists Amperon has made it on.

"We don't brand ourselves as a clean tech company," Kelly says, "but we have four of the top six or eight wind providers who have all invested in Amperon. So, there's something there."

Amperon, which originally founded in 2018 before relocating to Houston a couple of years ago, is providing technology that helps customers move toward a lower carbon future.

"If you look at our customer base, Amperon is the heart of the energy transition. And Houston is the heart of the energy transition," he says.

View All Listings